SB 959 would restrict patient access to customized medications by authorizing FDA oversight of what small pharmacies can prepare or "compound" in response to a physician's request, writes National Community Pharmacists Association CEO B. Douglas Hoey in response to a July 31 editorial stating that the bill leaves oversight of such pharmacies to states. The bill would inhibit pharmacies' ability to compound drugs to fill the void left by shortages, he writes. Hoey suggests that the Senate pass the anti-drug counterfeiting provisions of the proposal to prevent meningitis outbreaks and similar tragedies, but delay passing the sections on drug compounding until they can be revised.

Related Summaries